FDA Oversight: The FDA issued final guidance on “Postapproval Pregnancy Safety Studies,” pushing drug makers to collect clearer pregnancy safety data after approval—aimed at giving clinicians and patients more reliable counseling. Public Health Leadership: Adm. Brian Christine, a top hantavirus response figure, is drawing scrutiny over his medical background and past skepticism of federal health responses as CDC monitoring continues for additional hantavirus exposures. Drug Safety & Agency Stability: FDA leadership turmoil deepened after acting drug center chief Tracey Beth Hoeg confirmed she was dismissed following Commissioner Marty Makary’s sudden exit, raising fresh questions about drug oversight. Behavioral Health & Access: Texas Children’s Hospital agreed to stop puberty blockers, pay penalties, and open a “detransition clinic” after a DOJ/state settlement. Medicaid Pulse (Local): Medicaid billing data show fast-rising spending in multiple categories—like Irvine’s alcohol and drug abuse treatment claims surging to $7.04M in 2024 and Richmond’s temporary national codes climbing 10.3% to $33.96M. Food Safety: Arsenic was found in some apple and grape juices above drinking-water standards, prompting recalls in rare cases.